ArticleJournal of cardiothoracic surgery2026
Global trends of tranexamic acid in cardiac surgery: a bibliometric and visualized analysis via CiteSpace.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study sought to systematically and visually map the research landscape of tranexamic acid (TXA) in cardiac surgery, including its current status, evolutionary trends, key research hotspots, and emerging frontiers, through bibliometric analysis.
methodsOn April 8, 2025, all publications related to TXA application in cardiac surgery were retrieved from the Web of Science Core Collection (WOSCC) database. Using the CiteSpace tool, we conducted a comprehensive bibliometric analysis of key metrics, including annual publication output, contributing countries and institutions, core author collaboration networks, and keyword co-occurrence patterns.
resultsA total of 272 eligible documents were included in the final analysis. Wang Yang and Yuan Su were identified as core leading scholars in this field, while the United States and Harvard University emerged as the most productive country and institution, respectively. Keyword co-occurrence analysis revealed that primary research hotspots centered on cardiopulmonary bypass, aprotinin, perioperative blood loss, double-blind controlled trials, allogeneic transfusion, fibrinolysis inhibition, ε-aminocaproic acid, and risk assessment. Meanwhile, emerging research frontiers were found to focus on TXA-associated seizures, pharmacokinetic profiles in cardiac surgery populations, and optimized clinical management strategies.
conclusionsThis bibliometric analysis provides a systematic overview of the research status, evolutionary trends, key hotspots, and emerging frontiers of TXA in cardiac surgery. The findings can assist clinicians, researchers, and policymakers in prioritizing research agendas, identifying collaborative opportunities, and exploring innovative directions to advance the safe and effective use of TXA in cardiac surgical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.